Author

F. Dufour

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Organism:human· 4 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1

Frequent Co-Authors

E. Chapeaublanc· 4 shared F. Radvanyi· 4 shared I. Bernard-Pierrot· 4 shared J. Fontugne· 4 shared Y. Allory· 4 shared A. De Reynies· 3 shared A. Kamoun· 3 shared C. Krucker· 3 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

E. Chapeaublanc

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

H. Lang, C. Beraud, L. Cabel, M. Lassalle, J. Fontugne, C. Krucker, F. Dufour, C. S. Groeneveld, V. Dixon, X. Meng, A. Kamoun, E. Chapeaublanc, A. De Reynies, X. Game, P. Rischmann, , T. Massfelder

The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.

Frontiers in Oncology · Aug 11, 2022Peer-reviewedCancer Biology

Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks

H. Neyret-Kahn, J. Fontugne, X.-Y. Meng, C. S. Groeneveld, L. Cabel, T. Ye, E. Guyon, C. Krucker, F. Dufour, E. Chapeaublanc, A. Rapinat, D. C. B. Jeffery, Y. Neuzillet, T. Lebret, D. Gentien, , F. Radvanyi

The paper identifies super-enhancer networks regulating bladder cancer subtypes through transcription factors, showing their role in cell identity and inflammatory response suppression.

bioRxiv · Jan 11, 2022Cancer Biology

FGFR3 activating mutations induce luminal-like papillary bladder tumor formation and favor a male gender bias.

M. Shi, A. Moreno-Vega, J. Fontugne, X.-Y. Meng, F. Dufour, A. Kamoun, S. V. Lindskrog, A. Rapinat, C. Dunois-Larde, M.-L. Lapage, E. Chapeaublanc, O. Levrel, T. Lebret, A. Almeida, A. De Reynies, , I. BERNARD-PIERROT

This study shows FGFR3-S249C mutations drive luminal-like papillary bladder tumors in mice and correlate with male gender bias and AR activity in human tumors.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology

Physiological System Dysregulation in Gene Expression Correlates Negatively with Age

F. Dufour, P.-E. Jacques, A. A. Cohen

The paper identifies 230 gene ontology systems with negative DM-age correlations in human peripheral blood, suggesting loss of responsiveness during aging.

bioRxiv · Sep 9, 2020 · PreprintCell Biology

PPARG is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities.

L. Coutos-Thevenot, S. Beji, H. Neyret-Kahn, Q. Pippo, J. Fontugne, J. Osz, C. Krucker, C. Dos Santos Groeneveld, F. Dufour, A. Kamoun, M. Ley, E. Chapeaublanc, A. De Reynies, T. Lebret, Y. Allory, , I. BERNARD-PIERROT

The paper identifies PPARγ as a tumor suppressor in basal bladder tumors and suggests therapeutic opportunities through PPARγ activation.

bioRxiv · Dec 9, 2019 · PreprintCancer Biology